Holen Sie sich die Stockscreener-App
11.62
0.77%
-0.09
Handel nachbörslich:
11.60
-0.02
-0.17%
Schlusskurs vom Vortag:
$11.71
Offen:
$11.695
24-Stunden-Volumen:
2.96M
Relative Volume:
0.63
Marktkapitalisierung:
$1.25B
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-2.1204
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
+0.17%
1M Leistung:
-4.13%
6M Leistung:
+27.76%
1J Leistung:
-45.37%
1-Tages-Spanne:
$11.29
$11.83
1-Wochen-Bereich:
$11.06
$12.46
52-Wochen-Spanne:
$5.90
$23.76
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.62 | 1.22B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Cathie Wood’s ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia - Investing.com
Panic Selling: Is Intellia Therapeutics Inc. benefiting from interest rate changesJuly 2025 Drop Watch & Verified High Yield Trade Plans - khodrobank.com
Signal strength of Intellia Therapeutics Inc. stock in tech scannersQuarterly Earnings Report & Safe Capital Growth Tips - Newser
Does Intellia Therapeutics Inc. stock have upside surprise potentialJuly 2025 Big Picture & Real-Time Buy Zone Alerts - khodrobank.com
Real time alert setup for Intellia Therapeutics Inc. performanceJuly 2025 Snapshot & High Accuracy Trade Alerts - Newser
How to forecast Intellia Therapeutics Inc. trends using time series2025 Support & Resistance & High Yield Stock Recommendations - Newser
Intellia Therapeutics Inc. stock outlook for YEARPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
Leading vs lagging indicators on Intellia Therapeutics Inc. performanceWall Street Watch & Fast Gaining Stock Strategy Reports - Newser
What the charts say about Intellia Therapeutics Inc. todayPortfolio Value Report & Stepwise Swing Trade Plans - Newser
Tools to assess Intellia Therapeutics Inc.’s risk profileQuarterly Trade Report & Expert Verified Stock Movement Alerts - Newser
Why Intellia Therapeutics Inc. is moving today2025 EndofYear Setup & Safe Capital Investment Plans - Newser
Multi asset correlation models including Intellia Therapeutics Inc.Profit Target & Daily Oversold Stock Bounce Ideas - Newser
Merger Talk: Is Intellia Therapeutics Inc. benefiting from interest rate changesEarnings Performance Report & Stepwise Trade Signal Implementation - khodrobank.com
Is Intellia Therapeutics Inc. stock reversal real or fakeJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
How hedge fund analytics apply to Intellia Therapeutics Inc. stockWeekly Stock Recap & High Return Stock Watch Alerts - Newser
Will Intellia Therapeutics Inc. outperform tech stocksMarket Activity Report & Technical Buy Zone Confirmation - khodrobank.com
What’s next for Intellia Therapeutics Inc. stockMarket Sentiment Report & Real-Time Stock Price Movement Reports - khodrobank.com
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus - TradingView
Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider - GlobeNewswire Inc.
Intellia Therapeutics Inc. Stock Flags Risk Zone in Volatility Index getLinesFromResByArray error: size == 0 - thegnnews.com
Aug Levels: What’s next for Intellia Therapeutics Inc. stockInsider Selling & Short-Term Trading Opportunity Alerts - khodrobank.com
Is Intellia Therapeutics Inc. building a consolidation base2025 EndofYear Setup & Safe Capital Investment Plans - Newser
Pattern recognition hints at Intellia Therapeutics Inc. upside2025 Market WrapUp & High Accuracy Swing Entry Alerts - Newser
Why is Intellia Therapeutics Inc. stock going upJuly 2025 Update & High Accuracy Trade Signal Alerts - khodrobank.com
Is Intellia Therapeutics Inc. stock good for income investorsPortfolio Performance Report & Consistent Profit Trade Alerts - خودرو بانک
Insider Buy: Can Intellia Therapeutics Inc. navigate macro headwindsWeekly Trade Recap & Weekly Top Performers Watchlists - khodrobank.com
Why big players are pouring millions in THIS biotech stock - TradingView
Key metrics from Intellia Therapeutics Inc.’s quarterly dataJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - Newser
Intellia Therapeutics Inc. stock chart pattern explainedJuly 2025 Review & Weekly High Potential Stock Alerts - Newser
Applying sector rotation models to Intellia Therapeutics Inc.Trade Entry Report & Fast Entry High Yield Stock Tips - Newser
Intellia Therapeutics Inc. stock prediction for this week2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Using Python tools to backtest Intellia Therapeutics Inc. strategiesJuly 2025 Breakouts & AI Powered Market Trend Analysis - Newser
Chart based analysis of Intellia Therapeutics Inc. trendsJuly 2025 Patterns & Safe Entry Momentum Tips - Newser
ARK Investment buys 560K shares of Intellia Therapeutics - MSN
Detecting support and resistance levels for Intellia Therapeutics Inc.Portfolio Risk Summary & Low Drawdown Trading Techniques - Newser
Is Intellia Therapeutics Inc. a candidate for recovery playJuly 2025 Institutional & Scalable Portfolio Growth Methods - Newser
Will Intellia Therapeutics Inc. bounce back from current support2025 Dividend Review & Risk Controlled Daily Trade Plans - Newser
Is Intellia Therapeutics Inc. trending in predictive chart modelsOil Prices & Free Technical Confirmation Trade Alerts - Newser
Cathie Wood Invests $4M in Intellia Therapeutics, Trims Stakes in Roku and DraftKings - AInvest
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 23 '25 |
Sale |
14.02 |
7,462 |
104,617 |
106,062 |
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):